Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

BioElectronics Cooperation (BIEL)

978 Posts
Pagina: «« 1 ... 43 44 45 46 47 ... 49 »» | Laatste | Omlaag ↓
  3. [verwijderd] 17 november 2009 07:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    BioElectronics Corp.
    FREDERICK, MD--(Marketwire - November 16, 2009) - BioElectronics Corp. (PINKSHEETS: BIEL) today announced that its disposable drug-free anti-inflammatory devices proved to be significantly more effective than acetaminophen in a clinical study of Delayed Onset Muscle Soreness (DOMS).
    The study tested the effectiveness of ActiPatch® Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion.

    Bron: www.marketwire.com/press-release/Bioe...
  5. [verwijderd] 9 december 2009 16:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    welshterrier schreef:

    weer down hier vandaag 0,0800
    zakt wel erg ver weg hier.
    word weer interessant om op te pikken.

    0,0445 -0,0045 -9,18%
  6. aldel 10 december 2009 19:52

    • aldel

      Lid sinds: 05 mrt 2003

      Laatste bezoek: 04 mei 2024

    • Aanbevelingen

      Ontvangen: 11

      Gegeven: 4

    •    Aantal posts: 285

    Dit aandeel zal voor de FDA beslissing flink stijgen en als in Q3 de financiele positie wordt weergeven zullen veel grote beleggers ook inzien dat BIEL een goede investering is.
    Is in de afgelopende dagen voor de 15 dec flink naar beneden gekelderd.
  10. Demenkovets 15 december 2009 18:19

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    BioElectronics to Become Fully Reporting Company
    With Financial Audit Nearing Completion BioElectronics to Offer Full Financials and Increased Transparency to Investors

    * Press Release
    * Source: BioElectronics Corporation
    * On 10:00 am EST, Monday December 14, 2009

    FREDERICK, MD--(Marketwire - 12/14/09) - BioElectronics Corp. (Pinksheets:BIEL - News), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the Company would soon become a fully reporting company. The related filings will offer investors in BioElectronics full transparency into the Company's financials and financial operations.

    "As we indicated several months ago, BioElectronics has engaged a professional auditing firm to review our financials in order to provide our investors, distributors and other stakeholders an accurate and unbiased evaluation of our financial position. I am happy to announce today that the audit is now almost complete and that no major issues have been raised. We are expecting the auditing firm to issue its report over the very short term," commented Andrew Whelan, CEO of BioElectronics.

    The completion of the audit and the availability of the auditor's report will allow BioElectronics to soon file the required documentation in order to become a fully reporting company.

    Mr. Whelan continued, "Over the past few quarters we have made great strides in improving our financial condition. We have paid off all of our institutionally owned convertible debt, greatly improved our working capital position, and significantly improved our financial ratios. We are very proud of our current balance sheet and the progress we have made during this period. As a result, we believe we are very well positioned to manage the meaningful revenue growth we expect during 2010 and beyond."
  11. Demenkovets 30 december 2009 17:15

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    BioElectronics Ends 2009 with International Product and Partner Gains

    Source: BioElectronics Corp. On Wednesday December 30, 2009, 10:00 am EST

    FREDERICK, Md.--(BUSINESS WIRE)--BioElectronics Corp. (PINKSHEETS: BIEL - News), the maker of inexpensive, disposable, drug-free anti-inflammatory devices, today announces product gains in the international market as well as new international distributor and marketing partnerships. As a result, BioElectronics is expecting significant gains in international markets throughout 2010.

    Mr. Andrew Whelan, CEO of BioElectronics provides the following update to investors and other stakeholders:

    “Earlier in 2009, we had stated that our corporate priorities were the completion of clinical studies, United States Food and Drug Administration (FDA) filings and the building of our brands. I am pleased to say this management team has helped BioElectronics make excellent strides in these areas. This year we completed several major studies, which we filed in support of our FDA applications. Over the past two months our staff has worked diligently on additional applications seeking reclassification of our products from Class III to Class II. We believe this application contains compelling evidence that our products are not only effective, but are also safe. We remain confident that FDA clearance will be granted for our products. We believe our meeting, which is scheduled with the FDA for January, will allow us to make significant progress towards that goal. In the meantime, our international marketing efforts are moving into high gear with significant progress already being realized.

    “Today, we are announcing several significant international orders and partnerships. Our new distributor in Columbia, Health Tools S.A., has placed an order for both Allay, ActiPatch, and HealFast in support of the Latin American direct response TV campaign and its direct sales operations. We are also anticipating additional orders from our other Latin American partners. Additionally, our Turkey distributor has made a substantial commitment for product in support of direct response TV marketing campaigns in that region.

    “The management team has also been spending a considerable amount of time fostering relationships to drive sales in Asia. We recently finished our television advertising spots targeting China and those will be tested during the first quarter of 2010. Over the next several months members of the team will visit our Chinese marketing partner, Chinese government officials and television station executives in China. We view this as a very exciting revenue generation opportunity. We are also happy to announce we have completed negotiations with a well financed public company that will act as our marketing partner in Japan. Over the next few days we are expecting this partner to place a significant pre-order for product. We have long been excited about the Japanese market and believe it could ultimately be our largest market outside the United States.

    “The significant revenues we expect from these efforts will allow us to further strengthen our year-end balance sheet and position us well for substantial revenue growth in 2010 and beyond.”
  12. Demenkovets 25 januari 2010 16:29

    • Demenkovets

      Lid sinds: 24 feb 2009

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 114

      Gegeven: 54

    •    Aantal posts: 9.419

    BioElectronics Signs Deal to Enter Japanese Market

    Order from YesDTC Holdings is the Single Largest Order in Company History

    Press Release Source: BioElectronics Corp. On Monday January 25, 2010, 10:00 am

    FREDERICK, Md.--(BUSINESS WIRE)--BioElectronics Corp. (PINKSHEETS: BIEL - News), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the signing of a contract with YesDTC Holdings, Inc. (YESD.OB) to enter the Japanese market and receipt of the single largest product order and revenue commitment in company history.

    Shipments of initial products are expected to begin in the first quarter of 2010 with additional shipments expected throughout the year.

    “We are very excited about our entry into the Japanese market as we believe consumers will be highly receptive to our drug-free pain relieving and healing technology,” said Arnon Horev, BioElectronics Vice President of Marketing. “The initial order being placed via our Japanese distributor is far and away our single biggest order we have ever received and well into six figures. We plan on recognizing part of this order in Q4:09 with the remaining portions and Q1:10 and Q2:10 and to realize additional revenues through the rest of 2010. The realization of a significant portion of this revenue in Q4:09 will allow us to further strengthen our already strong balance sheet. We welcome YesDTC Holdings to our growing ranks of premium international distributors for our award winning pain relieving and healing products.”

    “At BioElectronics we are aggressively moving into many international markets,” Horev said. “As we have previously indicated, we have major initiatives underway in Latin America, Europe, Canada, and China among other international markets. We are expecting to begin airing television commercials in China during the first quarter of 2010 in support of our marketing efforts in that region and we are preparing to enter the Japanese market through our new distribution partner, YesDTC Holdings.”
  15. StephanO 6 maart 2010 17:51

    • StephanO

      Lid sinds: 21 mrt 2009

      Laatste bezoek: 14 sep 2023

    • Aanbevelingen

      Ontvangen: 30

      Gegeven: 6

    •    Aantal posts: 610

    Weer in de stijgende lijn. Ik heb dit aandeel al een geruime tijd.. Zit er al in vanaf 0.01 cent, heb het niet durven te verkopen, omdat ik verwachte dat hij eerder door zou gaan stijgen.. Nu is er in iedergeval weer sprake van een up-trent.. Ik zie nog een mooie toekomst voor dit bedrijf en zeker een leuke winst voor de mensen die hier nog in handelen..
  19. [verwijderd] 1 april 2010 14:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    BioElectronics Becomes Fully Reporting – Completes 2009 Audit, Files Form 10K with Securities and Exchange Commission
    Date : 04/01/2010 @ 8:00AM
    Source : Business Wire
    Stock : BioElectronics Corp. (BIEL)
    Quote : 0.0309 0.0 (0.00%) @ 8:34AM


    BioElectronics Becomes Fully Reporting – Completes 2009 Audit, Files Form 10K with Securities and Exchange Commission

    BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of its full year audit and the filing of Form 10K with the Securities and Exchange Commission. BioElectronics is now a fully reporting company.

    “We have now completed our audits through full year 2009. The process of providing full transparency is very important to us and we expect to remain fully compliant and reporting moving forward,” commented Andrew Whelan, CEO of BioElectronics Corp. “The recent developments at the Company are very exciting as our international distribution continues to grow and as we continue to work through the clearance process with the U.S. FDA. We are especially excited about the strength of our balance sheet, which shows strong financial ratios and a significant level of debt repayment throughout 2009. We believe BioElectronics is now very well positioned to move into the revenue growth phase we envision for the rest of this year and into next.”

    About BioElectronics Corporation

    BioElectronics Corporation
    is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see www.BioElectronicsCorp.com.
978 Posts
Pagina: «« 1 ... 43 44 45 46 47 ... 49 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.286
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.455
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.944
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.479
Aedifica 2 832
Aegon 3.257 320.092
AFC Ajax 537 7.018
Affimed NV 2 5.762
ageas 5.843 109.779
Agfa-Gevaert 13 1.862
Ahold 3.536 73.983
Air France - KLM 1.024 34.348
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.539
Allfunds Group 3 1.217
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 337
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.368
AMG 965 125.860
AMS 3 73
Amsterdam Commodities 303 6.522
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.162
Apollo Alternative Assets 1 17
Apple 5 316
Arcadis 251 8.623
Arcelor Mittal 2.024 318.667
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.113
Aroundtown SA 1 176
Arrowhead Research 5 9.283
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.702
ASML 1.762 77.058
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.669
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 06 mei

    1. China inkoopmanagersindex diensten april
    2. PostNL Q1-cijfers
    3. Siemens Healthineers Q1-cijfers
    4. TKH Q1-cijfers
    5. Dui inkoopmanagersindex diensten april (def)
    6. EU inkoopmanagersindex diensten april (def) 52,9
    7. VK inkoopmanagersindex diensten april (def)
    8. EU producentenprijzen maart
    9. Tyson Foods Q1-cijfers

  2. 07 mei

    1. Japan inkoopmanagersindex diensten april
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda